CSIMarket
 
Coherus Biosciences inc   (CHRS)
Other Ticker:  
 
 
Price: $2.2200 $0.05 2.304%
Day's High: $2.28 Week Perf: -2.2 %
Day's Low: $ 2.17 30 Day Perf: -18.38 %
Volume (M): 3,530 52 Wk High: $ 8.65
Volume (M$): $ 7,836 52 Wk Avg: $4.07
Open: $2.18 52 Wk Low: $1.43



 Market Capitalization (Millions $) 209
 Shares Outstanding (Millions) 94
 Employees 650
 Revenues (TTM) (Millions $) 257
 Net Income (TTM) (Millions $) -238
 Cash Flow (TTM) (Millions $) 39
 Capital Exp. (TTM) (Millions $) 0

Coherus Biosciences Inc
Coherus Biosciences Inc is a biotechnology company that is focused on the development and commercialization of biosimilar drugs.
Founded in 2010 and headquartered in Redwood City, California, Coherus is dedicated to increasing patient access to high-quality, affordable biologic medicines.
The company has a strong clinical and regulatory team with extensive experience in developing biosimilars and managing complex global development programs.
The company's leading product, UDENYCAe (pegfilgrastim-cbqv), is a biosimilar to Neulastae and is used to reduce the risk of infection in patients undergoing chemotherapy.
UDENYCAe was approved by the U.
S.
Food and Drug Administration (FDA) in November 2018 and has been launched in the United States through a collaboration with partner, Pfizer.
Coherus has also developed its own proprietary product, CHS-1420, a biosimilar to adalimumab (Humirae).
CHS-1420 has completed its Phase 3 clinical trial and is currently awaiting FDA approval.
Coherus has a robust pipeline of other biosimilar candidates targeting leading biologic drugs, such as bevacizumab (Avastine), ranibizumab (Lucentise), and aflibercept (Eyleae).
Coherus is also exploring the development of novel therapies in the areas of immuno-oncology and oncology supportive care.
In addition to its biosimilar development program, Coherus has established a strong intellectual property portfolio and has entered into several key collaborations to optimize the development and commercialization of its products.
The company is focused on maintaining a strong financial position and has raised over $1 billion in funding since its inception.
Overall, Coherus Biosciences Inc is a leading biosimilar company with a strong focus on delivering high-quality, affordable medicines for patients in need.


   Company Address: 333 Twin Dolphin Drive Redwood City 94065 CA
   Company Phone Number: 649-3530   Stock Exchange / Ticker: NASDAQ CHRS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Coherus Biosciences Inc

Coherus Biosciences Inc Makes Bold Strategic Move in Divesting Ophthalmology Franchise for $170 Million

Coherus Biosciences, a leading biopharmaceutical company, has recently completed the divestiture of its Ophthalmology Franchise with an upfront cash payment of $170 million. This strategic move aims to strengthen the company's capital structure and focus on its core business areas.
The divestiture of Coherus' Ophthalmology Franchise is a significant step towards streamlining its operations and reallocating resources into key therapeutic areas. By divesting the franchise, the company can optimize its business and concentrate on its primary goal of developing innovative and cost-effective treatment options for patients.

Contract

Coherus Biosciences Bolsters Financial Strength through Divestiture, Paving the Way for Biosimilar Innovation

Published Mon, Mar 4 2024 6:00 AM UTC

Coherus Biosciences, a leading biopharmaceutical company, has recently completed the divestiture of its Ophthalmology Franchise, resulting in an upfront cash payment of $170 million. This strategic move aims to strengthen the company's capital structure and focus on its core business areas.The divestiture of Coherus' Ophthalmology Franchise signifies a significant step towar...

Shares

Coherus BioSciences Invests in Talent for Future Growth

Published Fri, Feb 23 2024 10:33 PM UTC

Coherus BioSciences Announces New Employment Inducement Grants
On February 20, 2024, Coherus BioSciences, Inc. (Nasdaq: CHRS) granted options to purchase an aggregate of 170,000 shares of common stock to three newly hired employees. The options have a per share exercise price of $2.59, which was the closing trading price on the grant date. This includes 150,000 shares fo...

Financing Agreement

Coherus Biosciences Records Net Loss, but Amends Term Loan Agreement with Pharmakon Advisors, LP

Published Mon, Feb 5 2024 1:00 PM UTC



In recent news, Coherus Biosciences Inc, a leading biopharmaceutical company, has announced significant developments regarding its financial standing and debt obligations. Despite recording a cumulative net loss of $-217 million during the 12-month period ending in the third quarter of 2023, the company has managed to secure an amendment to its term loan agreement...

Financing Agreement

Coherus Biosciences Pivots towards Oncology with Strategic Transaction to Divest Ophthalmology Franchise

Published Mon, Jan 22 2024 6:15 AM UTC

Coherus Focuses on Oncology with Strategic Transaction
Coherus Biosciences Inc has recently announced a strategic transaction that aligns with the company's focus on oncology. The move comes after the company recorded a cumulative net loss of $-217 million during the 12 months ending in the third quarter of 2023.
In an effort to consolidate its operations and streaml...






 

Coherus Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com